科研级 Donanemab (多奈单抗 ), Anti-APP Recombinant Antibody, Research Grade Donanemab
Molecular Name
Donanemab
Size
1mg, 5mg
CAS Number
1931944-80-7
Isotype
IgG1 Kappa
Clonality
Monoclonal
Concentration
1mg/ml
Source
CHO Cells
Purity
≥95% as determined by SDS-PAGE
Buffer
Supplied in PBS, PH7.5
Target
APP[Homo sapiens]
Background
Donanemab (USAN, development code LY3002813) is a biological drug in trial to treat early symptoms of Alzheimer's disease. There is no cure or treatment for Alzheimer’s disease. Donanemab has shown positive results in Eli Lilly and Co.’s first two trials.